

- **Name:** Yoon-La Choi
  - **Current Position & Affiliation:** Professor  
Samsung Medical Center &  
Sungkyunkwan University, School of Medicine
  - **Country:** Korea
- 

- **Educational Background:**

- 1996.02 Seoul National University, College of Medicine (Dr.)
- 2001.02 Seoul National University, College of Medicine (M.D.)
- 2003.02 Seoul National University, College of Medicine (Ph.D.)

- **Professional Experience:**

- 2001.03 ~ 2002.02 Clinical Fellowship  
Department of Neuropathology,  
Seoul National University Hospital
- 2002.03 ~ 2003.07 Research Fellow  
National Research Lab (Laboratory of Immunogenetics),  
Department of Pathology, Seoul National University,  
College of Medicine
- 2003.08 ~ 2008.02 Clinical Instructor  
Department of Pathology,  
Samsung Medical Center & Sungkyunkwan University
- 2006.03 ~ 2007.12 Clinical Visiting Instructor  
Department of Pathology, Stanford University
- Present Professor  
Department of Pathology and Translational Genomics,  
Samsung Medical Center &  
Sungkyunkwan University, College of Medicine

- **Professional Organizations:**

- 2000 ~ Present : Association for Molecular Pathology, member
- 2002 ~ Present : Korean Breast Cancer Society, member
- 2002 ~ Present : Korea Genome Organization, member
- 2008 ~ Present : American Association for Cancer Research, member
- 2008 ~ Present : Korean Association for Lung Cancer, member
- 2013 ~ Present : The International Association for the Study of Lung Cancer, member

## • Main Scientific Publications:

Kim YJ, Lee G, Han J, Song K, Choi JS, Choi YL, Shin YK. UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. *Front Oncol.* 2020 Jan 23;9:1574

Hwang I, Choi YL, Lee H, Hwang S, Lee B, Yang H, Chelakkot C, Han J. Selection Strategies and Practical Application of BRAF V600E-mutated Non-Small Cell Lung Carcinoma. *Cancer Res Treat.* 2021 Nov 23.

Lee H, Han J, Choi YL. Real-World Analysis of the *EGFR* Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer. *Diagnostics (Basel).* 2021 Sep 17;11(9):1695.

Kim JH, Hong JH, Choi YL, Lee JA, Seo MK, Lee MS, An SB, Sung MJ, Cho NY, Kim SS, Shin YK, Kim S, Kang GH. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. *J Pathol.* 2021 Dec;255(4):399-411

Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, Ding Y, Lee SH, Powell E, Lee SK, Yu JH, Ching KA, Nam JY, Kim SW, Nam SJ, Kim JY, Cho SY, Park S, Kim J, Hwang S, Kim YJ, Bonato V, Fernandez D, Deng S, Wang S, Shin H, Kang ES, Park WY, Rejto PA, Bienkowska J, Kan Z. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. *Nat Commun.* 2020 Dec 2;11(1):6175.

Jung K, Choi JS, Koo BM, Kim YJ, Song JY, Sung M, Chang ES, Noh KW, An S, Lee MS, Song K, Lee H, Kim RN, Shin YK, Oh DY, Choi YL. TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis. *Cancer Res Treat.* 2021 Jan;53(1):9-24

Yun JW, Yang L, Park HY, Lee CW, Cha H, Shin HT, Noh KW, Choi YL, Park WY, Park PJ. Dysregulation of cancer genes by recurrent intergenic fusions. *Genome Biol.* 2020 Jul 6;21(1):166.

Lee MS, Jung K, Song JY, Sung MJ, Ahn SB, Lee B, Oh DY, Choi YL. *IRS2* Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer. *Mol Ther Oncolytics.* 2020 Jan 10;16:188-196.